On track to report initial Phase 1 data from HWK-007 and HWK-016 in 1H'27Initiated Phase 1 trial for HWK-206 in the U.S., the third Whitehawk program to enter the clinic in the last 12 months; HWK-206 received Fast
MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed SettingsHigh MUC16 Expression Was Associated with Poor
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLCFindings Reinforce the Scientific Rationale for HWK-007, Whitehawk's
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs ExperienceMORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a
MORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently
Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026Cash, cash equivalents and short-term investments of $190.0 million as of June 30, 2026,
Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (("Whitehawk, NASDAQ:WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will
SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination Findings
MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver
Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload VariationsHangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core
MORRISTOWN, N.J., May 20, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver
MORRISTOWN, N.J., May 15, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver
MORRISTOWN, N.J., May 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to
Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026Cash, cash equivalents and short-term investments balance of $123.0 million as of March 31, 2026, anticipated to
Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platformTumor regressions observed across various cancer models
